| Literature DB >> 32503854 |
Robert Bm Landewé1,2, Pedro M Machado3, Féline Kroon4, Hans Wj Bijlsma5, Gerd R Burmester6, Loreto Carmona7, Bernard Combe8, Massimo Galli9, Laure Gossec10,11, Annamaria Iagnocco12, John D Isaacs13, Xavier Mariette14,15, Iain McInnes16, Ulf Mueller-Ladner17, Peter Openshaw18, Josef S Smolen19, Tanja A Stamm20, Dieter Wiek21, Hendrik Schulze-Koops22.
Abstract
The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by SARS-CoV-2, COVID-19 and are meant for patients with rheumatic and musculoskeletal diseases (RMD) and their caregivers. A task force of 20 members was convened by EULAR that met several times by videoconferencing in April 2020. The task force finally agreed on five overarching principles and 13 recommendations covering four generic themes: (1) General measures and prevention of SARS-CoV-2 infection. (2) The management of RMD when local measures of social distancing are in effect. (3) The management of COVID-19 in the context of RMD. (4) The prevention of infections other than SARS-CoV-2. EULAR considers this set of recommendations as a 'living document' and a starting point, which will be updated as soon as promising new developments with potential impact on the care of patients with RMD become available. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: antirheumatic agents; epidemiology; health services research; patient care team; quality indicators, health care
Mesh：
Substances：
Year: 2020 PMID： 32503854 DOI： 10.1136/annrheumdis-2020-217877
Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 27.973